for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TRACON Pharmaceuticals Inc

TCON.OQ

Latest Trade

0.32USD

Change

-0.04(-11.89%)

Volume

124,913

Today's Range

0.31

 - 

0.36

52 Week Range

0.30

 - 

1.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.36
Open
0.36
Volume
124,913
3M AVG Volume
3.25
Today's High
0.36
Today's Low
0.31
52 Week High
1.73
52 Week Low
0.30
Shares Out (MIL)
29.94
Market Cap (MIL)
10.51
Forward P/E
-0.40
Dividend (Yield %)
--

Next Event

Q3 2019 TRACON Pharmaceuticals Inc Earnings Release

Latest Developments

More

Tracon Pharmaceuticals Says Qtrly Loss Per Share $0.21

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253

Tracon Pharmaceuticals Reports Qtrly Loss Per Share $0.24

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry

Biotechnology & Drugs

Contact Info

4350 La Jolla Village Dr Ste 800

+1.858.5500780

http://www.traconpharma.com/

Executive Leadership

Charles P. Theuer

President, Chief Executive Officer, Principal Financial Officer, Director

Scott B. Brown

Chief Accounting Officer, Principal Accounting Officer

Mark C. Wiggins

Chief Business Officer

William R. LaRue

Independent Director

Martin A. Mattingly

Independent Director

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.130

2017

-1.140

2018

-1.300

2019(E)

-0.873
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
73.92
LT Debt To Equity (MRQ)
45.49
Return on Investment (TTM)
-105.49
Return on Equity (TTM)
-73.32

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up